A NEW study published in the
New England Journal of Medicine
has found a link between the regular
use of aspirin after a diagnosis of
colon cancer, and better clinical
outcomes in patients with cancers
characterized by mutated PIK3CA
(the phosphatidylinositol-4,5-
bisphosphonate 3-kinase, catalytic
subunit alpha polypeptide) gene.
The study looked at data from
964 patients with rectal or colon
cancer including data on aspirin use
after diagnosis and the presence or
absence of PIK3CA mutation.
According to the results, regular
use of aspirin after diagnosis was
associated with longer survival in
patients with mutated-PIK3CA
colorectal cancer, but not among
patients with wild-type PIK3CA cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 26 Oct 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Oct 12
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.